« Zurück
Startseite /
Anti-Human HER-2 (Trastuzumab)

Anti-Human HER-2 (Trastuzumab)

ArtNr	LEIN-LT1500-1.0mg
Hersteller	Leinco Technologies
Menge	1 mg
Quantity options	1 mg 100 mg 25 mg 5 mg 50 mg Custom
Kategorie	Antibodies Primary Antibodies
Typ	Antibody Primary
Applikationen	FC, IHC, ELISA
Clon	4D5-8
Specific against	Human (Homo sapiens)
Host	Human
Purity	≥95% monomer by analytical SEC
Citations	1. Fendly, B. et al. (1990) Cancer Research 50: 1550-1558. 2. McBride, H. et al. (2019) Pharm Res. 36(12): 177. 3. Zielinski, C. et al. (1997) Int. J. Cancer 73: 875–879 4. Valone, FH. et al. (1995) J. Clin. Oncology 13 (9): 2281-92. 5. Hynes, NE. et al. (1993) Br J Cancer. 68(6): 1140–1145.
NCBI	2064
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Applications	Quality Tested by Leinco FC The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Manufacturer - Category	Recombinant Antibodies>Biosimilar Recombinant Antibodies
Manufacturer - Targets	HER-2/neu
Country of Origin	USA
Shipping Temperature	2 - 8°C Wet Ice
Storage Conditions	Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Product Description	Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
Background	Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
Pathogen Testing	To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Other Applications Reported In Literature	ELISA IHC CyTOF®
PubMed	HER-2/neu
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only.
FC Effector Activity	Active
RRID	AB_2893910
Concentration	≥ 5.0 mg/ml
Formulation	This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Antigen Distribution	Ubiquitous expression with highest expression levels found in the kidney, skin, esophagus, and small intestine.
Immunogen	Human epidermoid carcinoma cells (A431) over-expressing EGFR.
Regulatory Status	Research Use Only (RUO). Non-Therapeutic.
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-LT1500-1.0mg-safety-datasheet.pdf